Jump to main content
Jump to site search

Issue 1, 2014
Previous Article Next Article

Advances and critical concerns with the microfluidic enrichments of circulating tumor cells

Author affiliations

Abstract

Over the past two decades, circulating tumor cells (CTCs) have been widely recognized for their importance in clinical trials. While most enrichment methods for these cells have been conducted through the batch process due to their rarity in blood and the need for large sample volumes, the batch process leads to unavoidable cell loss. Given the heterogenetic features of CTCs, this cell loss may limit the validity of research that relies on the isolation of CTCs; such research includes cancer prognosis, diagnosis of minimal residual diseases, assessment of tumor sensitivity to anticancer drugs, and the personalization of anticancer therapies. Recent advances in microfluidic approaches have made it possible to enrich CTCs with a small degree of cell loss. In this review, we highlight several microfluidic-based positive and negative enrichment methods that are the subject of considerable research interest (e.g. EpCAM-dependent assay and EpCAM-independent assay) and suggest a microfluidic-based single cell analysis platform for the down-stream analysis of CTCs. We also discuss critical concerns and future directions for research.

Graphical abstract: Advances and critical concerns with the microfluidic enrichments of circulating tumor cells

Back to tab navigation

Publication details

The article was received on 10 May 2013, accepted on 05 Aug 2013 and first published on 07 Aug 2013


Article type: Critical Review
DOI: 10.1039/C3LC50582K
Citation: Lab Chip, 2014,14, 45-56
  •   Request permissions

    Advances and critical concerns with the microfluidic enrichments of circulating tumor cells

    K. Hyun and H. Jung, Lab Chip, 2014, 14, 45
    DOI: 10.1039/C3LC50582K

Search articles by author

Spotlight

Advertisements